Physician profile
Moses Ramos
NPI 1013137561
$7,349.58
in general payments reported to CMS, 2019-2025
28 companies · $946 in 2025
The $946 reported for 2025 was more than what 85% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $528 · 2021: $1,364 · 2022: $894 · 2023: $1,242 · 2024: $1,178 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.13 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,246.34 | 2019-2025 | Equetro, Equetro, Raldesy |
| Abbvie INC. | $708.89 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $648.22 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $566.31 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $509.43 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $488.24 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $447.56 | 2020-2025 | Trintellix |
| Tris Pharma INC | $409.73 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Lundbeck LLC | $378.22 | 2019-2024 | Rexulti |
| Corium, LLC | $377.45 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $198.20 | 2019-2023 | Ingrezza |
| Noven Therapeutics, LLC | $190.52 | 2023-2025 | Secuado, Xelstrym |
| Shire North American Group INC | $180.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $173.54 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $138.61 | 2021-2023 | Aristada, Lybalvi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $123.66 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $97.82 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $81.35 | 2023-2025 | Auvelity |
| Vertical Pharmaceuticals, LLC | $69.96 | 2019 | |
| Adlon Therapeutics L.P. | $59.77 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $54.98 | 2019-2021 | |
| Neos Therapeutics, Lp | $52.50 | 2019 | |
| Jazz Pharmaceuticals INC. | $41.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $33.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.32 | 2024 | Austedo Xr |
| Owp Pharmaceuticals, INC. | $19.82 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.28 | 2019 | |
| Neuronetics, INC. | $15.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moses Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.